Drug Profile
Respiratory syncytial virus vaccine - Sanofi
Latest Information Update: 08 Apr 2022
Price :
$50
*
At a glance
- Originator sanofi pasteur
- Class Respiratory syncytial virus vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Respiratory syncytial virus infections
Most Recent Events
- 19 Jan 2005 Aventis Pasteur is now called sanofi pasteur
- 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
- 21 May 2003 This vaccine is still in active development with Aventis Pasteur